Recent developments in glycine antagonists

Current Opinion in Investigational Drugs

Volumn 1, Issue 2, 2000, Pages 230-235

  Antolini, M ^a   Donati, D ^a   Micheli, F ^a  

^a GSK   (Italy)

Author keywords

Animal models; Anticonvulsant; Cerebral ischemia; Epilepsy; Glycine antagonist; Neuroprotectant; NMDA receptor; Pain; Parkinson's; Stroke

Indexed keywords

3 (2 CARBOXY 2 PHENYLETHENYL) 4,6 DICHLORO 1H INDOLE 2 CARBOXYLIC ACID; 4,6 DICHLORO 3 (2 OXO 1 PHENYL 3 PYRROLIDINYLIDENEMETHYL) 1H INDOLE 2 CARBOXYLIC ACID; 5 [4 AMINOMETHYL 2 (CARBOXYMETHOXY)PHENYLCARBAMOYLMETHYL] 9 CHLORO 6,7 DIHYDRO 1H,5H PYRIDO[1,2,3 DE]QUINOXALINE 2,3 DIONE; 5 AMINOMETHYL DERIVATIVE; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; 6,7 DIMETHYL 5 NITRO 2,3 QUINOXALINEDIONE; 7 CHLORO 1,2,5,10 TETRAHYDRO 4 HYDROXY 2 (4 METHOXY 2 METHYLPHENYL)PYRIDAZINO[4,5 B]QUINOLINE 1,10 DIONE; ACEA 1038; AMPA RECEPTOR AGONIST; BENZENE DERIVATIVE; BENZYLAMINE DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; DIZOCILPINE; GAVESTINEL; GAVESTINEL DERIVATIVE; GLYCINE RECEPTOR; GLYCINE RECEPTOR ANTAGONIST; GV 224029; HYDROQUINONE DERIVATIVE; KYNURENIC ACID DERIVATIVE; NERAMEXANE; OPIATE; PHENYTOIN; PHOSPHONOALKYL DERIVATIVE; PYRAZINE DERIVATIVE; PYRIDOPHTHLAZINE DERIVATIVE; PYRROLE DERIVATIVE; PYRROLIDINE DERIVATIVE; QUINOXALINE DERIVATIVE; UK 240455; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; EPILEPSY; EXPERIMENTAL MODEL; HUMAN; NEUROPROTECTION; NONHUMAN; PAIN; RECEPTOR AFFINITY; REVIEW; STROKE; STRUCTURE ACTIVITY RELATION;

ANIMALS; CLINICAL TRIALS; GLYCINE; GLYCINE AGENTS; HUMANS; NERVOUS SYSTEM DISEASES;

EID: 0033761659     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Protection against ischemic neuronal damage by drugs acting on excitatory neurotransmitters
2. Excitatory amino acid antagonists and their potential for the treatment of ischemic brain damage in man
3. The excitatory amino acid receptors: Their classes, pharmacology, and distinct properties in the function of the central nervous system
4. Excitatory amino acid transmitters
5. New treatments for acute stroke
6. Pharmacology of glutamate receptor antagonists in the kindling model of epilepsy
7. Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes
8. Glycine potentiates the NMDA response in cultured mouse brain neurons
9. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5
10. Non-competitive NMDA antagonists, acting on the glycine site
11. The glycine site on the NMDA receptor: Structure-activity relationships and therapeutic potential
12. Non competitive NMDA antagonists as drugs
13. Regulation of the NMDA receptor-channel complex by the strychnine-insensitive glycine site
14. The glycine site of the NMDA receptor-five years on
15. The glycine site on the NMDA receptor: Structure-activity relationships and possible therapeutic applications
16. Glycine-site antagonists and stroke
17. Pharmacological characterization of MDL 105,519, an NMDA receptor glycine site antagonist
18. 3H]MDL 105,519, a radiolabelled antagonist for the N-methyl-D-aspartate-associated glycine site, to pig cortical brain membranes
19. Substituted indole-2-carboxylates as in vivo potent antagonists acting at the strychnine-insensitive glycine binding site
20. Identification and pharmacological characterization of GV150526, a novel glycine antagonist as a potent neuroprotective agent
21. Novel synthesis of ethyl 3-(bromoacetyl)-4,6-dichloro-1H-indole-2-carboxylate as useful intermediate in the preparation of potential glycine site antagonists
22. Unusual synthesis of new glycine antagonists via sequential aldol condensation-lactonization-elimination reaction
23. Novel class of indole-2-carboxylates as potent glycine site NMDA antagonists
24. Substituted analogues of GV150526 as potent glycine binding site antagonists in animal models of cerebral ischemia
25. Cycloalkyl indol-2-carboxylates as useful tools for mapping the 'north-eastern' region of the glycine binding site associated with the NMDA receptor
26. Potent antihyperalgesic activity without tolerance produced by glycine site antagonist of N-methyl-D-aspartate receptor GV196771A
27. First time in human for GV196771: Interspecies scaling applied on dose selection
28. New synthesis of substituted 2-carboxyindole derivatives. Versatile introduction of a carbamoylethynyl moiety at the C(3) position
29. Synthesis of substituted indole-2-carboxylates: Versatile introduction of a carbomyl moiety at the C-3 position
30. Substituted indole-2-carboxylates as potent antagonists of the glycine binding site associated to the NMDA receptor
31. (E)-3-(2-(N-Phenylcarbamolyl)vinly)pyrrole-2-carboxylic acid derivatives. A novel class of glycine site antagonists
32. Pharmacology of 5-chloro-7-trifluoromethyl-1,4-dihydro-2,3-quinoxalinedione: A novel systematically active ionotropic glutamate receptor antagonist
33. ACEA-1328, an NMDA receptor antagonist, increases the potency of morphine and U50,488H in the tail flick test in mice
34. ACEA-1328, a NMDA receptor/glycine site antagonists, acutely potentiates antinociception and chronically attenuates tolerance induced by morphine
35. 5-Aminomethylquinoxaline-2,3-diones, part III: Arylamide derivavites as highly potent and selective glycine-site NMDA receptor antagonists
36. 5-Aminomethylquinoxaline-2,3-diones, part II: N-arylamide derivatives as novel NMDA/glycine and AMPA antagonists
37. N-phosphonoalkyl-5-aminomethylquinoxaline-2,3-diones: In vivo active AMPA and NMDA (glycine) antagonists
38. Synthesis and SAR of novel di- and trisubstituted 1,4-dihydroquinoxaline-2,3-diones related to licostinel (ACEA 1021) as NMDA/glycine site antagonists
39. Book of Abstracts of New Medicines from Heterocycles
40. Enzymatic resolution of 2-substituted tetrahydroquinolines. Convenient approaches to tricyclic quinoxalinediones as potent NMDA-glycine antagonists
41. Effects of the novel tricylic quinoxalinedione derivatives, SM-18400 and its analogs, on N-methyl-D-aspartate (NMDA) receptor-mediated synaptic transmission in the isolated neonatal rat spinal cord in vitro
42. Design and synthesis of novel quinoxaline-2,3-dione AMPA/GlyN receptor antagonists: Amino acid derivatives
43. 4,5- dihydro-1,2,4-triazolo[1,5-a]quinoxalin-4-ones: Excitatory amino acid antagonists with combined glycine/NMDA and AMPA receptor affinity
44. 5-(N-Oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: Novel, systematically active and broad spectrum antagonists for NMDA/glycine, AMPA and kainate receptors
45. 2,3-Dihydro-6,7-dichloro-pyridol[2,3-b]pyrazine-8-oxide as selective glycine antagonist with in vivo activity
46. Synthesis, glycine/NMDA and AMPA binding activity of some new 2,5,6-trioxopyrazino[2,2,3-de]quinoxalines and of their restricted analogs 2,5-dioxo-and 4,5-dioxoimidazo[1,5,4-de]quinoxalines
47. Pyridazino[4,5-b]quinolinediones: Novel glycine/N-methyl-D-aspartate antagonists for the treatment of stroke
48. A glycine site antagonist, ZD9379, reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion
49. Synthesis and SAR of 5-, 6-, 7- and 8-aza-3-artyl-4-hydroxyquinolin-2(1H)-ones as NMDA/glycine site antagonists
50. SAR and neuroprotective activity of a novel class of glycine antagonists
51. Novel systematically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: Electrophysiological, biochemical and behavioral characterization
52. Neuroprotection by novel antagonsits at the NMDA receptor channel and glycine(B) sites
53. GlycineB antagonists and partial agonists in rodent models of Parkinson's disease - Comparison with uncompetitive N-methyl-D-aspartate receptor antagonist
54. Anticonvulsant activity of 4-urea-5,7-dichlorokynurenic acid derivatives that are antagonists at the NMDA-associated glycine binding site
55. Spiro-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one derivatives are mixed AMPA and NMDA glycine-site antagonists active in vivo
56. Pyrrolidine-2,4-diones with affinity to the N-methyl-D-aspartate (glycine site) receptor. Part 2. 5-arylidene-pyrrolidine-2,3,4-trione 3-oximes as NMDA receptor antagonists
57. N-(Benzyloxycarbonyl)glycine esters and amides as new anticonvulsants
58. 3H]CGP 61594, the first photoaffinity ligand for the glycine site of NMDA receptors